Moleculin Biotech (NASDAQ:MBRX) released their financial report for the second quarter of 2017.
As quoted in the press release:

Walter Klemp, Chairman and CEO of Moleculin stated:“We are pleased with the results of this past quarter, especially in our recent achievements with the Mayo Clinic to supply WP1066 for a potential grant funded study, a discovery of a Metabolic Inhibitor with the potential to treat pancreatic cancer and signing a new technology license agreement with MD Anderson. We are also excited to have begun clinical testing site development efforts in Poland with our appointment of Bioscience SA as our Polish CRO. We look forward to submitting our IND for Annamycin for the treatment of relapsed or refractory AML and moving forward with the FDA to allow for clinical trials to begin.”

Click here to read the full press release.

Source: www.marketwired.com